Compare Ascendis Pharma A/S (ASND) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Schwab US Large Cap Growth ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Schwab US Large Cap Growth ETF trades at $34.58. Which is the better fit depends on your goals.
| ASND | SCHG | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $35.30 |
52-Week Low | $163.32 | $28.10 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SCHG trades at $34.65 with a 0.32% daily gain, showing bullish technical momentum with strong moving average support. The ETF's concentrated exposure to AI-driven tech leaders like Nvidia, Apple, and Microsoft positions it for growth amid projected multi-trillion dollar AI infrastructure spending. Recent institutional buying and positive analyst coverage highlight confidence in its large-cap growth strategy despite elevated valuations around 32x P/E.
The outlook remains positive given SCHG's strategic positioning in AI growth themes, though concentration risk in top holdings and sensitivity to interest rate changes present challenges. Current technical strength suggests near-term upside potential to resistance at $35, while long-term performance depends on sustained tech sector leadership and AI adoption trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
